Re: 6%

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: 6%

in response to

Re: 6%

fuzzyjr

posted on Dec 15, 2022 11:21AM

If management goes with the royalty revenue stream option, all monies go to ZCC.

If management goes with the sale of the ZEN-3694 option, all monies go to ZCC.

No monies go to RVX. RVX is a separate company.

Koo

1 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply